Health Logic Interactive Provides Product Update for MATLOC 1 Digital Diagnostic Device
Health Logic Interactive Inc. (TSXV: CHIP.H, OTCPK: CHYPF) announced updates on its MATLOC 1 digital diagnostic device, focusing on biomarkers for chronic kidney disease. Significant advancements include the completion of an optical measurement sub-system and testing of a fluid handling sub-system. The design of a urine sampling cartridge is underway, with user interaction studies expected to conclude by mid-July. The company aims for MATLOC 1 to integrate with lab-on-chip technology and plans to submit it for FDA review, supporting its mission for early CKD detection.
- Completion of optical measurement sub-system for MATLOC 1.
- Testing of fluid handling sub-system has been successful.
- Design efforts for urine sampling cartridge have commenced.
- User interaction study for MATLOC 1 to improve design is ongoing.
- None.
TSXV: CHIP.H
CALGARY, AB, July 7, 2021 /PRNewswire/ - Health Logic Interactive Inc. ("Health Logic" or the "Company") (TSXV: CHIP.H)(OTCPK: CHYPF), is pleased to announce its first update to our digital diagnostic device MATLOC 1. MATLOC 1 is the Company's proprietary diagnostic platform technology in development for the testing of different biomarkers, with a current focus on the biomarkers albumin and creatinine for chronic kidney disease (CKD) screening and eventual diagnosis.
Current development activities are focused on creating and testing functional sub-systems to inform the design of an integrated prototype for testing with end users. The Company is pleased to announce the optical measurement functional sub-system has been built and is actively generating data which will inform the development of both an albumin and creatinine test. A fluid handling sub-system has also been created and tested. The next step in fluid handling design relies on the design of the urine sampling cartridge. Design efforts for the cartridge commenced in the past week and are expected to continue through the month of July. A key tenet of the company's design philosophy is to place the user at the center of our development efforts. As such, a user-centric design brief has been created and is being tested in a user interaction study expected to be completed in mid-July.
"This is an exciting development as completion of the optical measurement and a fluid handling sub-system brings us even closer to integration of MATLOC 1 with our lab-on-chip technology. We continue to advance MATLOC 1 toward a functional prototype and to an expected submission with the United States Food and Drug Administration," stated David Barthel, CEO of Health Logic.
About the Company
Health Logic Interactive, through its wholly owned operating subsidiary My Health Logic, is developing and commercializing consumer focused handheld point-of-care diagnostic devices that connect to patient's smartphones and digital continued care platforms. The Company plans to use its patent pending lab-on-chip technology to provide rapid results and facilitate the transfer of that data from the diagnostic device to the patient's smartphone. The Company expects this data collection will allow it to better assess patient risk profiles and provide better patient outcomes. Our mission is to empower people with the ability to get early detection anytime, anywhere with actionable digital management for chronic kidney disease. For more information visit us at: www.healthlogicinteractive.com
Further information regarding Health Logic Interactive Inc. and its disclosure documents are available on SEDAR at www.sedar.com.
Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Notes
Certain statements contained in this press release constitute "forward-looking statements". All statements other than statements of historical fact contained in this press release, including, without limitation, those regarding the Company's belief that the MATLOC 1 device will successfully test different biomarkers including albumin and creatinine, the expected timing for design of a urine sampling cartridge, the anticipated timing for the user interaction study, the planned integration of the Company's technologies, the anticipated submission to the United States Food and Drug Administration, and the Company's strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words "believe", "expect", "aim", "intend", "plan", "continue", "will", "may", "would", "anticipate", "estimate", "forecast", "predict", "project", "seek", "should" or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only the Company's expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. Additional factors that could cause actual results, performance or achievements to differ materially include, but are not limited to the risk factors discussed in the Company's Management's Discussion and Analysis for the year ended December 31, 2020. Management provides forward-looking statements because it believes they provide useful information to investors when considering their investment objectives and cautions investors not to place undue reliance on forward-looking information. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company. These forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/health-logic-interactive-provides-product-update-for-matloc-1-digital-diagnostic-device-301326638.html
SOURCE Health Logic Interactive Inc.
FAQ
What is the latest development for CHYPF's MATLOC 1 device?
When is the user interaction study for MATLOC 1 expected to be completed?
What biomarkers is MATLOC 1 focusing on?
Is Health Logic planning to submit MATLOC 1 to the FDA?
